Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 15, 2025Journal of Clinical MedicineOpen Access

Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational Study

View Full Paper
Ask AI
Bookmark
Share

Authors

ELErmelinda LongoFPFanny Erika PalumboADAndrea Duminuco

Discussion

Loading...

Member takes

Overview

Observational study shows comparable outcomes for early and late responders in R/R AML, suggesting flexible treatment schedules are feasible.

Key Points

  • Treatment with HMA-VEN achieved a composite complete remission rate of 58% in R/R AML patients, demonstrating effectiveness.
  • No significant differences in overall survival were observed between early and late responders, implying flexibility in treatment timing is possible.
  • Patients treated with HMA-VEN reported manageable toxicities, including neutropenia, which is a common side effect of such therapies.
  • The study suggests that late responders do not face a prognostic disadvantage, indicating continued therapy may be beneficial.

Cite This Study

Longo et al. (2025) studied this question.

synapsesocial.com/papers/68c235ccb210217d6477203fhttps://doi.org/10.3390/jcm14155586
View Full Paper
Ask AI
Bookmark
Share